Lumanity is proud to be taking part at ISPOR Europe 2023, the leading health economics and outcomes research (HEOR) conference. ISPOR brings together global HEOR leaders, policy makers, regulators, researchers, academics, payers, patients, and patient groups under one roof to network and discuss this year’s topic ‘HEOR at the Nexus of Policy and Science’.

What we’re talking about at ISPOR 

With seismic policy changes on the horizon and increased focus on delivering value, this year we are encouraging pharmaceutical manufacturers to get ahead of the curve. We can help you avoid pitfalls and overcome obstacles by identifying them early and strategizing solutions for successful outcomes.

Continue reading to find out why time is of the essence and early planning is essential. Speak to our team at ISPOR to find out how we can help.

EU Health Technology Assessment Regulation

Time is ticking and implementation of joint clinical assessments in the European Union is a little over a year away. Speak to our team at ISPOR to find out how Lumanity can help you to prepare. Find out more about the regulation here.

Inflation Reduction
Act (IRA)

The IRA brings significant changes to US healthcare policies. Early preparation and strategic planning are crucial – let Lumanity equip you for IRA success. Find out more here.

Building Your Early Value Strategy

Success begins with the end in mind. Speak to our team at ISPOR to understand how Lumanity can help you avoid sub-optimal evidence packages, pricing failure and limited market access by planning early.

Global Real-World Data Networks

Speak to our teams at ISPOR to find out how we can make more efficient evidence generation and a stronger evidence base a reality by leveraging the PHARMO Data Network to coordinate pan-European observational research that meets new HTA requirements.

Meet with Our Experts at Booth C2-005

Stop by our booth (C2-005) to meet our experts in person. If you are interested in scheduling a meeting with one of our experts, please don’t hesitate to reach out using the link below.

Nick Sullivan, Global President, HEOR at Lumanity

Nick Sullivan
Global President, HEOR

Ron Akehurst
Executive Chair, HEOR

Daniel Gladwell
Chief Scientific Officer

David Robinson
Senior Vice President, Commercial Strategy & Operations

Julie Roiz
Senior Vice President, Regional Head, Europe HEOR

Alexis Kuchins
Vice President, HEOR Global Commercial Partnerships

Ann-Marie Chapman

Ann-Marie Chapman
Vice President, Strategic Solutions, HEOR

Meena Venkatachalam
Head of Global RWE Consulting

Nikita Jeswani
Head of Global RWE Sales

Suzette Matthijsse
Senior Director, EU Head of Modelling and Analytics

Amit Ahuja
Senior Director, HEOR

Linda Murphy, Senior Director at Lumanity

Linda Murphy
Senior Director, HEOR

Andrea Khan
Director, HEOR Global Commercial Partnerships

Jane Moorhouse, Principal Insight Analyst at Lumanity

Jane Moorhouse
Director, HEOR

Nathan Johnson
Director, Patient-Centered Outcomes

Shayna Egan
Director, Patient-Centered Outcomes

Amy Boyers
Principal Research Associate

Hannah Kilvert
Principal Statistician

Laure Weijers
Senior Research Associate, Patient-Centered Outcomes

Colin Burke
Senior Health Economist

Leandro Guerra Primo
Senior Health Economist

Emily Breislin
Associate Consultant

Jetty Overbeek
PHARMO Institute

Josine Kuiper
PHARMO Institute

Short Course

Sunday, 12 November | 08:00-12:00

Felicity Lamrock, Gianluca Baio, Howard Thom, Rose Hart.

Health Economic Modeling in R: A Hands-on Introduction

Lumanity’s Rose Hart is a presenter in this highly practical course. The course outlines the computational and transparency advantages of using R, for those used to health economic modelling using Microsoft Excel. This course explores the use of R for health economic modelling in the context of health economics and outcomes research (HEOR) and faculty will guide the participants through practical examples of HEOR.

Breakout Session

Monday, 13 November | 17:00 – 18:00

Moderator: Josie Godfrey
Panelists: Ron Akehurst, Fleur Chandler, Jill Carlton.

Measuring Health Related Quality of Life in Pediatric Life Limiting Progressive Diseases. Whose Perspective Are We Measuring?

Lumanity’s Ron Akehurst joins the panel discussing the different approaches to including HRQoL in paediatric life-limiting conditions in HTA. Which perspective (proxy, patient or population) is most useful to decision-making, how to take into account the impact of disease progression over a lifetime and how best to interpret the results of HRQoL measures in clinical trials.

HTA Case Study

Tuesday, 14 November | 10:15 – 11:15

Matthijsse S, Akehurst R, Gladwell D, Wasem J.

HTA Reforms in Germany: Implications for Pharmaceutical Pricing and Reimbursement in Germany and the EU

Lumanity experts, joined by former chairperson of the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) Drug Price Arbitration Board Juergen Wasem, explore the most significant implications for pharmaceutical pricing and reimbursement in Germany following the approval of the cost-containment law and how the new bill interacts with the new European Regulation on HTA.


Monday, 13 November Poster Session 1 | 10:30 – 13:30

Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK
Schurer M, Murphy L, Horscroft J, Chetty M, Hudson R.

Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study
Fox CP, Sugrue D, Toron F, Tyas E, Cooper M, Richards J, Williams P.

Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
Tzanetakos C, Psarra M, Batsi M, Patterson K, Vostitsanou Z, Gourzoulidis G.

Health-Related Quality of Life and Its Drivers for Patients Living with Cystic Fibrosis in Five Key European Countries: A Systematic Review
Verma R, Telukuntla V, Ahuja A.

Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR
Brown L, Jindal S, Smith M.

The Burden of Illness of Vasomotor Symptoms Associated with Menopause
Malacan J, Rosa Bolling K, Haberland C, Gaianu L, Smith N, Woods M, Smith M.

Use of Clinical Outcome Assessments in Health Technology Appraisals for Rare Disease Indications: A Review of UK, US, and Canadian Submissions
Jones E, Hyman J, Weijers L, Johnson N.

Monday, 13 November Poster Session 2 | 15:30 – 18:30

Combining Causal Inference and Within-Trial Economic Evaluation Methods to Assess the Cost-Effectiveness of a Mental Health Service Using Real-World Data: The Quasi-Experimental Adapt Study
Franklin M, Porter A, De Vocht F, Kearns B, Latimer N, Hernandez M, Young T, Kidger J.

Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review
Jindal S, Sharma A, Mahajan K, Saharia P, Mohan V.

Economic Evaluations of Medical Devices Used in the Treatment of Breast Cancer: A Systematic Review
Madan T, Rohilla A, Taneja A.

Estimating Health-Related Quality of Life in Fabry Disease for Patients Treated with Enzyme-Replacement Therapy in the BALANCE Randomized Controlled Trial
Lee B, Hemstock M, Stevenson A, Stork R, Azimpour K.

Menopause: More Than Just Vasomotor Symptoms
Malacan J, Rosa Bolling K, Haberland C, Gaianu L, Smith N, Woods M, Smith M.

Tuesday, 14 November Poster Session 3 | 10:30 – 13:30

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
Ray-Coquard I, Pautier P, Muston D, Monberg MJ, Swami S, Chaker O, Bensimon L, Lange S, Kulakova M, Durand Zaleski I, Marié L.

Economic Burden of Wilson’s Disease: A Systematic Review
Garg J, Mandal A, Khurana IS, Ahuja A.

Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review
Ghoshal D, Madan T, Taneja A.

Impact in Health Outcomes of PD-(L)1 Inhibitors to Treat Early Stages Cancers in Switzerland
Favre-Bulle A, Sönmez D, Stankovic M, Neves C, Mantaian T, Frei C, Schaefer S, Flori M, Aguiar-Ibáñez R.

Methods for incorporating external evidence: a comparison of their impact on extrapolations and uncertainty estimates using a melanoma case-study
Kearns B, Wolff H, Kilvert H.

Tuesday, 14 November Poster Session 4 | 15:30 – 18:30

A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs
Lister J, Paisley S, Tappenden P, Carroll C.

Economic Burden of Cystic Fibrosis in Five Key European Countries: A systematic Review
Verma R, Telukuntla V, Ahuja A.

Health-Related Quality of Life and Its Drivers for Patients Living with Glioblastoma in Europe: A Systematic Review
Telukuntla V, Azad M, Verma R, Ahuja A.

Impact of Roflumilast Foam 0.3% on Patient-Reported Quality of Life in Seborrheic Dermatitis: An Analysis of Stratum Data for Patients Unresponsive or Intolerant to Topical Corticosteroids
Chu DH, Lee J, Stephenson B, Bannister B, Hickey C, Westley T, Zirwas M.

Patient Voice in Smc Technology Appraisals for Orphan and Ultra-Orphan Diseases
Gupta A, Jindal S, Mahajan K, Sharma A, Saharia P.

Wednesday, 15 November Poster Session 5 | 09:00 – 11:30

Associations of Sex and Race with Relative Efficacy in Clinical Trials
Zhao P, Qu T, Shi S.

Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Swami S, Hale O, Thornton I, Muston D, Monberg MJ, Monk BJ.

Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review
Garg J, Madan T, Taneja A.

Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods
Lister J, Paisley S, Tappenden P, Carroll C.

NICE Technology Appraisals Based on Single-Arm Trials in 2022 – What Can We Learn from Them?
Guerra Primo L, Matthijsse S, Westley T.

Our Partner the PHARMO Institute

Our partner the PHARMO Institute will be at ISPOR Europe! You can meet some of their experts at our booth and below is a list of posters the team will be presenting.

Monday 13 November Poster Session 1 | 10:30 – 13:30

EXACOS-CV healthcare resource utilisation in Spain, Germany, the Netherlands and Canada
Parsekar K, Kossack N, Hernández I, Vogelmeier CF, Kolb N, Baak B, Swart-Polinder K, Simons S, Bengtsson C, Vojinovic-Dees D, Sin D, Hawkins N, McMullen S, Pham T, Corregidor García C, Martinez N, Sánchez-Covisa Hernández J, Abram M, Halbach M, van Burk L, Randhawa A, Nordon C.

Opportunities for the Use of Real World Data in Perinatal Pharmacoepidemiological Research: The Pharmo Perinatal Research Network (PPRN)
Houben E, Swart-Polinder K, Steegers E, Herings R.

Tuesday 14 November Poster Session 3 | 10:30 – 13:30

Survival and Drug Treatment Patterns in Multiple Myeloma Patients Exposed to an Anti-CD38 Monoclonal Antibody: A Proteasome Inhibitor and an Immunomodulatory Imide Drugs
Hoveling L, de Jong H, Penning-van Beest F, Holthuis E, Smits E, Dalhuisen S, Dinkla S, Herings R.

Tuesday 14 November Poster Session 4 | 15:30 – 18:30

Coded diagnoses versus proxy-based diagnoses in primary care: registration by general practitioners in the PHARMO GP data
Overbeek J, Baak B, Herings R, Swart-Polinder K.

Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People with Type 2 Diabetes
van den Berg JM, Blom MT, Swart-Polinder KMA, Overbeek J, Remmelzwaal S, Elders PJM, Herings RMC.